| Issue 44 – Nov. 22, 2013 |
“I don’t think any good cancer center director would be worth their weight in salt if they weren’t worried about something at night,” said Mark Evers, director of University of Kentucky Markey Cancer Center.
20131203_14
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
The FDA Oncologic Drugs Advisory Committee July 17 recommended against approval of a Blenrep-based regimen for the treatment of relapsed or refractory multiple myeloma, citing unacceptable rates of ocular toxicity and overall poor tolerability of the drug.
In cancer care, imaging has become a marvel of modern medicine. Advances in scanner technology, reconstruction algorithms, contrast agents, and diagnostic protocols have radically improved our ability to detect, track, and understand disease. Clinically, imaging is fast, accurate, and central to decision-making.
NIH has announced that it will no longer be issuing Notices of Funding Opportunities exclusively supporting animal models.
President Trump said he would impose tariffs on pharmaceutical products and semiconductors as soon as Aug. 1.
The Centers for Medicare & Medicaid Services published a proposed rule, which it says aligns with Trump’s “Big Beautiful Bill.”
